 This issue of JCP Visuals is available in Adobe Acrobat Portable Document Format (PDF). For a description of PDF and Adobe Acrobat Reader, please visit our Online Media Page. Download the Posttest (if you prefer not to take the Posttest online for instant credit) |
To obtain credit, please
study the activity material and complete the posttest as
instructed. CME Objectives After completing this educational activity, participants should be able to:
Statement of Need and Purpose A substantial number of children who have attention-deficit/hyperactivity disorder (ADHD) continue to have symptoms well into adulthood. In adults, ADHD is often associated with substance abuse as well as co-occurring anxiety, mood, and disruptive disorders. Physicians often fail to consider, detect, or treat adults for ADHD, due to a lack of information on the diagnosis and treatment of ADHD. This educational activity was designed to meet the needs of participants in the CME activities of Physicians Postgraduate Press, Inc. who have requested information on the diagnosis and management of ADHD in adults. There are no prerequisites for participating in this activity. Accreditation Statement Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Physicians Postgraduate Press, Inc. designates this educational activity for up to 1 Category 1 credit toward the AMA Physician's Recognition Award. Each participant should claim only those credits that he/she actually spent in the educational activity. Date of Original Release/Review This JCP Visuals was published in August 2003. This activity is eligible for CME credit through August 31, 2005. The latest review of this material was June 2003. Faculty Joseph Biederman, M.D., Chair Lenard A. Adler, M.D. C. Brendan Montano, M.D. Kevin R. Murphy, Ph.D. Thomas J. Spencer, M.D. Margaret D. Weiss, M.D. Timothy E. Wilens, M.D. Faculty Disclosure In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Biederman has received research support from Shire Richwood, Eli Lilly, Wyeth, Pfizer, Cephalon, Novartis, Janssen, Noven Pharmaceutical, Stanley Foundation, the National Institute of Mental Health (NIMH), the National Institute of Child Health & Human Development, and the National Institute on Drug Abuse (NIDA); is a member of the speakers bureaus for GlaxoSmithKline, Eli Lilly, Pfizer, Novartis, Wyeth, Shire Richwood, ALZA, and Cephalon; and is a member of the advisory boards for Eli Lilly, Celltech, Shire Richwood, Novartis, Noven Pharmaceutical, ALZA, McNeil, and Cephalon. Dr. Adler is a consultant for, has received grant/research support and honoraria from, and is a member of the speakers or advisory boards for Novartis, Abbott, Eli Lilly, Pfizer, Merck, McNeil, and Johnson & Johnson. Dr. Montano is a consultant for Eli Lilly, GlaxoSmithKline, Organon, Forest, Roche, and Wyeth; has received grant/research support from Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline; and has received honoraria from and is a member of the speakers or advisory boards for Eli Lilly, GlaxoSmithKline, Forest, Organon, and Wyeth. Dr. Spencer has received research support from Abbott, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Celltech, Novartis, Pfizer, Shire Richwood, and Wyeth; is a member of the speakers bureaus of Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Celltech, Novartis, Shire Richwood, and Wyeth; and is a consultant for Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Novartis, Pfizer, and Shire Richwood. Dr. Weiss has received grant/research support from Circa Dia and Eli Lilly and is a consultant for, has received honoraria from, and is a member of the speakers or advisory boards of Eli Lilly, GlaxoSmithKline, Circa Dia, Shire Richwood, Novartis, Purdue Pharma, and Janssen. Dr. Wilens is a consultant for, has received grant/research support from, and is a member of the speakers bureaus of Abbott, Celltech, Eli Lilly, McNeil, NIDA, NIMH, Novartis, Pfizer, Shire Richwood, and GlaxoSmithKline. Dr. Murphy has no financial relationships to disclose significant to the presentation. Disclosure of Off-Label Usage The chair has determined that, to the best of his knowledge, bupropion and desipramine are not approved by the U.S. Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder and topiramate is not approved for the treatment of bipolar disorder. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Acknowledgment This JCP Visuals was derived from the symposium “Diagnosing and Treating Attention-Deficit/Hyperactivity Disorder in Adults,” which was held January 17, 2003, in Boston, Mass., and was independently developed by the Physicians Postgraduate Press, Inc. Office of Continuing Medical Education pursuant to an unrestricted educational grant from Eli Lilly and Company. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter. |